  Currently, there are 14 ongoing clinical studies on low dose radiotherapy
(LDRT) for COVID-19 pneumonia. An underlying assumption is that irradiation of
about 1 Gy is effective at ameliorating viral pneumonia. Its rationale,
however, relies on early human case series or animal studies mostly obtained in
the pre-antibiotic era, where rigorous statistical analyses were not performed.
It therefore remains unclear whether those early data support such assumptions.
With standard statistical survival models, and based on a systematic literature
review, we re-analyzed 14 radiobiological animal datasets in which animals
received mostly fractionated doses of radiation before or after bacterial/viral
inoculation, and assessing various health endpoints (mortality, pneumonia
morbidity). In most datasets absorbed doses did not exceed 7 Gy. Various
different model systems and types of challenging infection are considered. For
7 studies that evaluated post-inoculation radiation exposure (more relevant to
LDRT for COVID-19 pneumonia) the results are heterogeneous, with 2 studies
showing a significant increase (p<0.001) and another showing a significant
decrease (p<0.001) in mortality associated with radiation exposure. For
pre-inoculation exposure the results are also heterogeneous, with 6 datasets
showing a significant increase (p<0.01) in mortality risk associated with
radiation exposure and the other 2 showing a significant decrease (p<0.05) in
mortality risk. Collectively, these data do not provide clear support for
reductions in morbidity or mortality associated with post-infection radiation
exposure. For pre-infection radiation exposure the inconsistency of direction
of effect makes this body of data difficult to interpret. Nevertheless, one
must be cautious about adducing evidence from the published reports of these
old animal datasets.
